Kuno: The association between famotidine and in‐hospital mortality of patients with COVID‐19

All Studies Meta Analysis

▶

All Studies Meta Analysis Recent:

Download Image

Kuno, 9,565 patient famotidine late treatment PSM study: no change in mortality [p=0.97] https://c19p.org/kuno2

copied to clipboard

The association between famotidine and in‐hospital mortality of patients with COVID‐19

Kuno et al., Journal of Medical Virology, doi:10.1002/jmv.27375

11 Oct 2021 Source PDF Share Tweet

PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality.

Important missing comments or errors? Let us know.

risk of death, no change, OR 1.00, p = 0.97, treatment 1,593, control 7,972, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Kuno et al., 11 Oct 2021, retrospective, propensity score matching, USA, peer-reviewed, 4 authors, study period 1 March, 2020 - 30 March, 2021.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Famotidine All

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit